WALTHAM, Mass. -
May 8, 2023 -
PRLog -- Temple Therapeutics (http://www.templerx.com/)
, a biotechnology company pioneering a female-focused precision medicine approach, presented new in vitro and in vivo data on TTX335o, the first drug candidate from the company's platform that won (https://www.hollandbio.nl/
nieuws/temple-
therapeutics-
b-v-wins-eurostars-
grant-for-novel-
oncology-program/)
the Eurostar Eureka (https://www.eurekanetwork.org/)
peer-reviewed grant process in 2019 for ovarian cancer, and the novel ovarian cell target, lemur tyrosine kinase 3 (LMTK3). The new data was provided at a poster presentation (https://aacrjournals.org/
cancerres/article/
83/7_Supplement/
5556/721702)
at the American Association of Cancer Research (AACR (https://www.aacr.org/
meeting/aacr-
annual-meeting-
2023/)) Annual Meeting, which took place on April 14-19, 2023 in Orlando.
"While survival rates for ovarian cancer are creeping up to the 50% level, it is clear that the vast majority of women are diagnosed too late," said Sanj Singh (
https://www.linkedin.com/in/sanj-singh-64300a6/), CEO of Temple Therapeutics. "It has been referred to as the silent killer by some, and others have described it as the neglected or ignored killer. Despite its lethality as the most dangerous gynecological cancer, the field has been sparsely researched. We are changing that. As we recognize World Ovarian Cancer Day today, we can do better. Our sisters, aunts, spouses, friends, co-workers, mothers, and grandmothers are affected."
TTX335o is based on the breakthrough discovery of LMTK3 and its mechanism of action. Increased levels of LMTK3 have been shown to affect the transcription of genes promoting DNA repair, cell viability, and tumorigenesis which activates cell death pathways specific to cancer cells without harming normal cells.
Preclinical data presented at AACR 2023 included:
- LMTK3 protein was detected in 98% of ovarian cancer tissues collected from 204 patients in various stages and major histology and localized in the nucleus of health cells and in the cytoplasm of tumor cells.
- Risk of death among ovarian cancer patients with more cytoplasmic than nuclear LMTK3 levels was particularly high during the first year after diagnosis. This suggests cytoplasmic LMTK3 expression correlates with poor survival which serves as a potential prognostic marker for ovarian cancer patient outcomes (p<.01).
- TTX335o specifically targets apoptosis, a major determinant in uncontrolled cell growth in ovarian cancer through a novel integrin (αV/β1), monomeric myeloperoxidase (mMPO), and LMTK3 signaling pathways. Knocking down LMTK3 also induced cell death in ovarian cancer, and more importantly, did not harm normal cells.
- In vitro and in vivo studies seem to validate LMTK3 as a specific target and predictor of clinical outcomes in ovarian cancer.
Account Phone Number